Coronavirus Notebook: A UK Catapult, A Russian Vaccine, And A Cuban Therapy
Executive Summary
The UK BioIndustry Association has welcomed the government’s fresh investment in COVID-19 vaccine manufacturing capacity, while Sanofi and GSK are striking European and US deals for their vaccine candidate. A number of potential therapies are also being developed, including products based on interferon and hyperimmune globulin, but Roche/Chugai’s Actemra (tocilizumab) looks like a non-runner.
You may also be interested in...
UK Bags More COVID-19 Vaccines And Backs J&J, Novavax Trials
With the Janssen and Novavax deals, the UK has now secured access to six different candidates across four different vaccine types.
Coronavirus Notebook: WHO Accelerator Project Languishes, Novel Treatments Are Explored, Gilead Submits US Remdesivir Filing
Gilead files for US approval of remdesivir and boosts investment in manufacturing capacity, more funding is needed for the global ACT Accelerator initiative, and the US and China are rated among the worst responders to the COVID-19 pandemic.
Coronavirus Update: Roche's Actemra Fails In Phase III COVID Study
Disappointment as Roche/Chugai antibody tocilizumab misses most endpoints.